These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38133292)

  • 1. The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms.
    Cross RW; Wiethoff CM; Brown-Augsburger P; Berens S; Blackbourne J; Liu L; Wu X; Tetreault J; Dodd C; Sina R; Witcher DR; Newcomb D; Frost D; Wilcox A; Borisevich V; Agans KN; Woolsey C; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Strifler B; Ebert P; Higgs R; Beall A; Chanda S; Riva L; Yin X; Geisbert TW
    Pathogens; 2023 Nov; 12(12):. PubMed ID: 38133292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
    Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
    Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
    Sims JT; Poorbaugh J; Chang CY; Holzer TR; Zhang L; Engle SM; Beasley S; Doman TN; Naughton L; Higgs RE; Kallewaard N; Benschop RJ
    J Transl Med; 2022 Mar; 20(1):134. PubMed ID: 35303909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
    Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
    JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
    Ernest CS; Chien JY; Patel DR; Chigutsa E
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
    Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes MD; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ;
    Nat Microbiol; 2022 Nov; 7(11):1906-1917. PubMed ID: 36289399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.
    Palazzo AG; Zizza A; Nuzzo M; Urciuoli C; Scardia S; Romano A; Guido M; Grima P
    Curr Med Res Opin; 2022 Jul; 38(7):1055-1057. PubMed ID: 35608093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
    Benschop RJ; Tuttle JL; Zhang L; Poorbaugh J; Kallewaard NL; Vaillancourt P; Crisp M; Trinh TNV; Freitas JJ; Beasley S; Daniels M; Haustrup N; Higgs RE; Nirula A; Cohen MS; Marovich M
    Sci Transl Med; 2022 Jul; 14(655):eabn3041. PubMed ID: 35679357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
    Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
    medRxiv; 2021 Dec; ():. PubMed ID: 34981077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.
    Ramirez SI; Grifoni A; Weiskopf D; Parikh UM; Heaps A; Faraji F; Sieg SF; Ritz J; Moser C; Eron JJ; Currier JS; Klekotka P; Sette A; Wohl DA; Daar ES; Hughes MD; Chew KW; Smith DM; Crotty S;
    JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36378539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
    Thomas S; Smatti MK; Ouhtit A; Cyprian FS; Almaslamani MA; Thani AA; Yassine HM
    Mol Immunol; 2022 Dec; 152():172-182. PubMed ID: 36371813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
    Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
    Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG.
    Wang X; Li M; Lu P; Li C; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Wang P
    Pathogens; 2023 Aug; 12(9):. PubMed ID: 37764916
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.